Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Anti-Fungal (Pharmacy Action) TM
Active ingredients: clotrimazole
What it is used for
A broad spectrum antifungal for the topical treatment of fungal skin infections, including tinea, athlete's foot, ringworm, and candidal infections such as nappy rash.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Topical
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White, smooth semi-solid cream.
Do I need a prescription?
This medicine is available from a pharmacy without prescription.It is
Is this medicine subsidised?
This medicine was verified as being available on the Repatriation Schedule of Pharmaceutical Benefits (RPBS) on November 1, 2018. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
To access RPBS medicines you must hold a DVA Gold Card, DVA Orange Card or DVA White Card (for some medicines only). To learn about Department of Veterans' Affairs health cards, visit Department of Veterans' Affairs.
Pregnant or planning a pregnancy?
For the active ingredient clotrimazole
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Oral thrush (monoliasis, oral candidiasis, OC) information | myVMC
Oral thrush (candidiasis) is a yeast infection that occurs in the mouth. It is caused by the fungus Candida albicans. Anti-fungals are used in treatment.
Read more on myVMC – Virtual Medical Centre website
Griseofulvin - ACD
Griseofulvin is used to treat fungal infections of the scalp, skin and nails.
Read more on Australasian College of Dermatologists website
Dandruff - myDr.com.au
Dandruff is when your scalp sheds excessive amounts of larger-than-normal skin flakes. These flakes stick to the hair shafts, eventually falling on the collars and shoulders of clothes.
Read more on myDr website
Resolve Plus 1.0 Cream - myDr.com.au
Resolve Plus 1.0 Cream - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Nipple thrush (candidiasis, Candida infection) information | myVMC
Breast and nipple thrush is a yeast infection of the nipple and breast caused by the fungal organism Candida albicans. It is common with breastfeeding.
Read more on myVMC – Virtual Medical Centre website
SB 5B Capsules - myDr.com.au
SB 5B Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Voriconazole APOTEX Powder for infusion - myDr.com.au
Voriconazole APOTEX Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Chemists' Own Amer-Fine Nail Lacquer - myDr.com.au
Chemists' Own Amer-Fine Nail Lacquer - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluconazole Claris Solution for infusion - myDr.com.au
Fluconazole Claris Solution for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Voriconazole MYX Powder for injection - myDr.com.au
Voriconazole MYX Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Top results
Antifungal agents for infants and children with invasive fungal infections | Cochrane
Invasive fungal infections are a significant problem for children whose immune system is not functioning properly. The majority of the children have cancer. Antifungal medications can be given when these children develop a fever (for example a fever occurring when the white cells or neutrophils are low during chemotherapy) or when an infection has been formally identified (as in candidaemia, candidiasis and invasive aspergillosis). The antifungal agents that were compared appear equally efficacious. Pooling the data from the few studies that were available suggest kidney damage was less likely with a lipid preparation of amphotericin B compared with conventional amphotericin B. It is reasonable to recommend a lipid preparation of amphotericin B, if cost permits. No significant differences have been observed in children when other antifungal agents have been compared. More studies in children evaluating available antifungal are required to further clarify any benefits with regard to the risk of dying, prospects of complete recovery and drug toxicities.
Read more on Cochrane (Australasian Centre) website
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients | Cochrane
Read more on Cochrane (Australasian Centre) website
Oral antifungal drugs for treating athlete's foot (tinea pedis) | Cochrane
Athlete's foot (tinea pedis) is a fungal infection of the feet that is easily spread and difficult to get rid of. This review compared different oral antifungal drugs (i.e. drugs taken by mouth), and it included 15 trials, involving 1438 participants. There are several different kinds of oral treatments, and the trials we found considered all the oral drugs used to treat athlete's foot. We found terbinafine and itraconazole to be more effective than placebo. And we found terbinafine to be more effective than griseofulvin. Griseofulvin is a treatment that was developed much earlier than the new treatments, such as terbinafine and itraconazole; these newer treatments tend to be most evaluated. Trials of other drugs were not large enough to show differences between them. All drugs had side-effects; gastrointestinal effects were the most common.
Read more on Cochrane (Australasian Centre) website
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients | Cochrane
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
Read more on Cochrane (Australasian Centre) website
Cyclosporine for treating rheumatoid arthritis | Cochrane
This review included three trials with a total of 318 patients. A statistically significant decrease in the number of tender and swollen joints was found for patients taking cyclosporine when compared to those taking placebo. Significant improvements in pain and function were also found for those patients taking cyclosporine. More side effects occurred in the cyclosporine group compared to the placebo group.
Read more on Cochrane (Australasian Centre) website
Prevention of fungal infections in patients with cancer with antifungal drugs | Cochrane
Read more on Cochrane (Australasian Centre) website
Prevention of fungal infections in patients with cancer with amphotericin B | Cochrane
Read more on Cochrane (Australasian Centre) website
Cyclosporine A for induction of remission in severe ulcerative colitis | Cochrane
Ulcerative colitis (UC) is a chronic inflammation of the large bowel. Symptoms include bloody diarrhea and abdominal pain. The disease can also have manifestations outside the bowel with involvement of the joints, skin, eyes and liver. While the 'first line' treatment for a severe attack of UC is usually steroids (either as pills or intravenously) the options for patients not responding to steroids are limited and include surgical removal of the large bowel. Cyclosporine A (CsA), a drug effective in preventing transplant organ rejection by suppressing the immune system, was tried in severe UC with encouraging results in the early 1990's. The aim of this review was to assess the effectiveness of CsA for severe UC. The literature search identified 36 studies. Only 2 studies were of high methodological quality and both support the use of CsA in UC patients with a severe attack. However, both studies were small (involving only 50 patients altogether) and limited in the length of follow-up (from a few weeks up to a year). There is limited evidence that cyclosporine is more effective than standard treatment for severe ulcerative colitis. The conclusion of the review is that while the data concerning the use of CsA in severe UC are encouraging, more studies are needed.
Read more on Cochrane (Australasian Centre) website
Prevention of fungal infections in cancer patients with amphotericin B or fluconazole | Cochrane
Read more on Cochrane (Australasian Centre) website
Prevention and treatment of fungal infections with nystatin in severely immunodepressed patients | Cochrane
Read more on Cochrane (Australasian Centre) website
